HCW Biologics Inc. (HCWB) Fair Value 2026

HCWB · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-28, HCW Biologics Inc. (HCWB) trades at $3.43. QOC: 4.2/10. Value Trap Risk: 63/100 (DANGER). 1/13 models active.

Key Facts

Ticker
HCWB
Price
$3.43
Quality Score
4.2/10
Value Trap Risk
63/100
Models Active
1/13
Last Updated
Strength: PWERM suggests +259.2% upside with 31% confidence
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give HCWB?

1 Intrinsic Value Models vs. Current Price ($3.43)

Core Models (Unlocked)
Model Fair Value Upside
Option-Based · Medium Conviction
 $12.32 +259.2%

All Models Active

All 1 models are displayed above.

What Is HCW Biologics Inc. (HCWB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, HCW Biologics Inc.'s intrinsic value is estimated at a median fair value of $12.32. At a current market price of $3.43, 1 of 1 active valuation models identify upside potential, projecting a median implied return of +259.2%.

What Do the Models Say About HCWB?

1 of 13 models are currently active for HCWB. All 1 active models suggest the stock trades below fair value. See which stocks rank higher →

How Does HCWB Rank in Biotechnology?

Among 625 Biotechnology stocks, HCWB ranks #506 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For HCW Biologics Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is HCWB a Value Trap?

CirclFi's Value Trap algorithm assigns HCWB a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for HCW Biologics Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, HCW Biologics Inc. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones. The elevated Value Trap score, however, warrants additional due diligence.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HCWB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HCWB's 1 active models, average confidence is 31%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy HCW Biologics Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BBLGBone Biologics CorporationQOC 4.2RVPHReviva Pharmaceuticals Holdings, Inc.QOC 4.2SYRESpyre Therapeutics, Inc.QOC 4.2AGTXAgentix Corp.QOC 4.2NVCTNuvectis Pharma, Inc.QOC 4.2TOVXTheriva Biologics, Inc.QOC 4.2SPROSpero Therapeutics, Inc.QOC 7.4WHWKWhitehawk Therapeutics, Inc.QOC 5.7FBLGFibroBiologics, Inc.QOC 4.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BBLG · RVPH · SYRE · AGTX · NVCT · TOVX · SPRO · WHWK · FBLG · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to HCWB?

4 companies across all industries closest to HCWB’s Quality of Company score of 4.2/10.

AMIXAutonomix Medical, Inc.QOC 4.2XELBXcel Brands, Inc.QOC 4.2DPLSDarkPulse, Inc.QOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: AMIX · XELB · DPLS · NVDA

Where Does HCWB Sit in CirclFi's Biotechnology Rankings?

HCWB is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About HCW Biologics Inc.’s Valuation?

What is HCW Biologics Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for HCW Biologics Inc. (HCWB). The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HCWB overvalued or undervalued right now?

At $3.43, 1 of 1 active models suggest HCWB may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits HCW Biologics Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.2 mean for HCWB?

HCW Biologics Inc.'s QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HCWB?

CirclFi analyzes HCWB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is HCWB a value trap in 2026?

HCW Biologics Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns HCW Biologics Inc. (HCWB) a Quality of Company score of 4.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/HCWB/ · Methodology
Primary sources for this HCWB valuation
  • Financial statements: HCW Biologics Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001828673) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HCWB as of ; valuations recomputed .